The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Analysis of the Gene Coding for the BRCA2-Interacting Protein PALB2 in Familial and Sporadic Pancreatic Cancer
Open accessAbstract
Dear Sir: Current evidence indicates that about 5%–10% of pancreatic cancer has a familial component, although the vast majority of pancreatic cancer families remain unexplained. 1 PALB2 is a recently identified breast cancer susceptibility gene whose protein is closely associated with BRCA2, and is essential for BRCA2 anchorage to nuclear structures. This functional relationship made PALB2 a candidate gene for susceptibility to BRCA2-related cancers such as pancreas cancer. Recently, Jones et al2 screened 96 familial pancreatic cancer patients, 16 of whom had 1 first-degree relative with pancreatic cancer and 80 had ≥2 additional relatives with pancreatic cancer, ≥1 of which was first degree.2 Truncating PALB2 mutations were identified in 3 patients (3.1%) and there was no difference in average age of cancer onset between mutation-positive and -negative families. We sought to screen a larger cohort of pancreatic cancer cases, including both familial and sporadic types, to determine the wider contribution of PALB2 gene mutations in pancreatic cancer. We selected a total of 254 individuals with pancreas cancer (148 male, 106 female) at a median age of diagnosis of 61 years. Patients were identified between 1997 and 2007 via clinic-based recruitment in Toronto and Montreal and through either the Familial Gastrointestinal Cancer Registry at Mount Sinai Hospital in Toronto or the population-based Ontario Pancreas Cancer Study. In total, 203 patients were recruited in Toronto and 51 in Montreal. All probands were confirmed to have pancreatic adenocarcinoma by pathology report; 101 pro-bands had a family history of pancreatic cancer, of which 32 had 2 affected first-degree relatives. In these 101 cases, 74 had 1 affected relative, 18 had 2 affected relatives, 7 had 3 affected relatives, and 2 cases had >3 affected relatives (Table 1). Sixty probands had a family history of breast/ovarian cancer, including 21 cases with a family history of pancreatic cancer (included above). Because the cases were ascertained through pancreas cancer studies, the family history of breast cancer or ovarian cancer was not strong, with most families having a single relative affected, and no family having a BRCAPRO score >0.12 (ie, these were not primarily familial breast/ovarian cancer families with 1 or 2 additional cases of pancreas cancer). The median age at diagnosis of pancreatic cancer cases with no family history was 49 years (range, 31–85); 55% of these were <50 years old and 66% were <60 years old at diagnosis. Genomic DNA was obtained from blood, saliva, or buccal cells using standard extraction methods. Before analysis, 20 ng of total genomic DNA was used for whole genome amplification according to the manufacturer’s instructions using the Repli-g Mini Kit (Qiagen, Mississauga, Ontario, Canada). We screened the 13 coding exons of PALB2 by sequencing (n = 83) or high-resolution melt analysis (n = 171), which has similar sensitivity to sequencing.3 Samples with variants were reamplified by polymerase chain reaction (PCR) using the original, non–whole-genome-amplified DNA as template and the PCR product was sequenced in forward and reverse directions for confirmation. We performed multiplex ligation-dependent probe amplification assay (MLPA) for PALB2 on 228 samples where we had sufficient DNA of adequate quality, as previously described by Foulkes et al.4 Table 1 Pancreas Cancer Cases We identified a heterozygous, 6.7-kb germline deletion including exons 12 and 13 of PALB2 in a patient who was affected by breast and then pancreas cancer (ages 47 and 61, respectively) and whose mother died of pancreas cancer at age 83 (Figure 1). This result was confirmed by long range PCR (Takara Bio Inc., Madison, WI) using 2 different primer pairs, which determined the deleted region to span a region from the middle of intron 11 (2.7 kb from the beginning of exon 12), up to 1.8kb after exon 13. This deletion would disrupt the PALB2 WD40 motif, which is required for interaction with the BRCA2 protein. 5 Aside from the exonic deletion, 2 previously unreported missense variants (S285L and T911I) were identified, but neither were predicted to be pathogenic. Both these variants were seen in young-onset pancreas cancer cases (41 years and 48 years) with no family history. A number of previously reported variants were also identified (Table 2). Figure 1 (A) Pedigree of the proband (shown by arrow). PA, pancreatic cancer; BR, breast cancer. (B) MLPA showing deletion of exon 12 (161-bp fragment) and exon 3 (338-bp fragment). (C) Diagram of the deleted region showing the obligate core deletion as defined ... Table 2 Other Variants Detected in PALB2 The main purpose of the study by Jones et al2 was to illustrate that exomic sequencing could be used to identify genes conferring a substantial risk of cancer, in the absence of linkage or other localizing information. After identification of a PALB2 germ-line mutation in a pancreas cancer case with a family history of pancreatic cancer, truncating mutations were found in 3 other individuals, all of whom had a personal and family history of pancreas cancer. Here, we studied a more varied set of pancreas cancer cases, with fewer probands with very strong family histories of pancreas cancer, but more cases with family histories of other BRCA2-related cancers, and 13 cases diagnosed under the age of 40. We found only 1 deleterious mutation, a 2-exon deletion, which is only the second described case of a PALB2 exonic deletion, the other being reported in a case of Fanconi anemia.6 To date, PALB2 exonic deletions have not been reported in breast cancer families.7 Taking the 2 sets of data together, we conclude that germ-line mutations in PALB2 are a rare cause of pancreas cancer, whether hereditary, familial, or sporadic. Of note, 4 of the 5 PALB2-related pancreas families identified to date include ≥1 case of breast cancer and in 2 families mutations were seen in individuals with both breast and pancreatic cancer (a total of 9 cases in our study had both breast and pancreas cancer). It may be the case that investigating PALB2 will be worthwhile in individuals with very strong family histories of pancreas cancer, or where there is a concomitant history of breast cancer, but based on the findings presented herein, routine screening of PALB2 in individuals with, or at risk of pancreas cancer is difficult to justify. If PALB2 mutation screening is undertaken, it should include MLPA for exonic deletions. As is seen in breast cancer,8 the penetrance for these very rare disease-causing variants seems to be high.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826
Fanconi anemia is associated with a defect in the BRCA2 partner PALB2
Xia, B., Dorsman, J. C., Ameziane, N., de Vries, Y., Rooimans, M. A., Sheng, Q., Pals, G., Errami, A., Gluckman, E., Llera, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1942 · Cited by 465
Cited by
Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Li, D., Xie, K., Wolff, R., & Abbruzzese, J. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15841-8 · Cited by 1,719
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors
Klein, A. P. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00457-x · Cited by 1,258
Recent progress in pancreatic cancer
Wolfgang, C. L., Herman, J. M., Laheru, D. A., Klein, A. P., Erdek, M. A., Fishman, E. K., & Hruban, R. H. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21190 · Cited by 910
Metadata
- Authors
- Tischkowitz, M. D., Sabbaghian, N., Hamel, N., Borgida, A., Rosner, C., Taherian, N., Srivastava, A., Holter, S., Rothenmund, H., Ghadirian, P., Foulkes, W. D., & Gallinger, S.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 137
- Issue
- 3
- Pages
- 1183-1186
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2047956375
- Cited by
- 189
- References
- 2
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of the Gene Coding for the BRCA2-Interacting Protein PALB2 in Familial and Sporadic Pancreatic Cancer. https://app.cochat.ai/papers/10.1053/j.gastro.2009.06.055
- The paper
- Tischkowitz, M. D., Sabbaghian, N., Hamel, N., Borgida, A., Rosner, C., Taherian, N., Srivastava, A., Holter, S., Rothenmund, H., Ghadirian, P., Foulkes, W. D., & Gallinger, S. (2009). Analysis of the Gene Coding for the BRCA2-Interacting Protein PALB2 in Familial and Sporadic Pancreatic Cancer. Gastroenterology. https://doi.org/10.1053/j.gastro.2009.06.055
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.